Boca Pharmacal LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boca Pharmacal LLC
The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.
Valeant attributes 14% organic growth in U.S. sales to Bausch + Lomb acquisition, disputing Allergan assertion that the deal has not borne fruit. Vertex sees evidence of sustained benefit for CF patients in Kalydeco long-term usage study. Other updates from the second quarter earnings calls, in brief.
Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.
The acquisitive specialty pharma will buy privately-held generics firm Dava Pharmaceuticals for $575 million in cash and potentially another $25 million based on the achievement of certain sales milestones.
- Generic Drugs
- OTC, Consumer